SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-257860
Filing Date
2023-10-18
Accepted
2023-10-17 18:35:59
Documents
13
Period of Report
2023-10-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d570836d8k.htm   iXBRL 8-K 47969
2 EX-99.1 d570836dex991.htm EX-99.1 16104
  Complete submission text file 0001193125-23-257860.txt   195846

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tals-20231017.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tals-20231017_lab.xml EX-101.LAB 17980
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tals-20231017_pre.xml EX-101.PRE 11256
7 EXTRACTED XBRL INSTANCE DOCUMENT d570836d8k_htm.xml XML 3347
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 231330571
SIC: 2836 Biological Products, (No Diagnostic Substances)